Sanofi has opened its first digitally-enabled continuous manufacturing facility which, it says, ushers in the next-generation of biotech manufacturing.
Based in Framingham, Massachusetts, the new facility features leading-edge technology that connects the production process with research and development, paving the way for improved commercialisation of important new medicines for patients.
This facility accelerates the recent transformation of Sanofi’s Industrial Affairs organisation to focus on biologics-based therapies, in line with the transformation of the company’s R&D pipeline.
The ramping up of bio-pharmaceutical production capacities is a key pillar to achieving Sanofi’s ambition to establish the gold standard in the bio-pharmaceutical industry.
“Our Framingham facility leads the way in delivering the next generation of biologics manufacturing, leveraging intensified, continuous processing in a fully integrated digitally powered facility,” said Philippe Luscan, Executive Vice President of Global Industrial Affairs at Sanofi.
“This opening demonstrates we are at the leading edge of innovation and manufacturing excellence, helping us to shape the future of both our company and the industry.”